https://www.biopharmawatch.com/news/IRTC/kuehn-law-investigates-irhythm-technologies BiopharmaWatch en 2026-08-08T19:35:00.000Z Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm https://www.biopharmawatch.com/news/CMMB/online-casino-features-and-offerings BiopharmaWatch en 2026-08-08T01:26:30.000Z They Possess Totally Your Preferent Game ( And And So Around ) _ innenfor Norge Start Playing rollero-norge.com https://www.biopharmawatch.com/news/ISPC/ispecimen-closes-5-million-public-offering BiopharmaWatch en 2026-08-07T20:30:00.000Z iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/INCY/incyte-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-08-07T20:30:00.000Z Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SRRK/scholar-rock-fda-review-apitegromab-sma BiopharmaWatch en 2026-08-07T20:20:00.000Z Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-07T20:08:14.609Z Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/BRVE/braveheart-bio-upsized-ipo-2026 BiopharmaWatch en 2026-08-07T20:05:00.000Z Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/ENTX/entera-announces-q2-2026-results-business-updates BiopharmaWatch en 2026-08-07T20:05:00.000Z Entera Announces Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/ATYR/atyr-pharma-q2-2026-results-efzofitimod-prioritization BiopharmaWatch en 2026-08-07T20:01:00.000Z aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-conference-call-fda-review BiopharmaWatch en 2026-08-07T20:01:00.000Z NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans https://www.biopharmawatch.com/news/IMCC/im-cannabis-raises-250000-convertible-note-financing BiopharmaWatch en 2026-08-07T20:01:00.000Z IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing https://www.biopharmawatch.com/news/GRAL/grail-fda-advisory-meeting-galleri-test-review BiopharmaWatch en 2026-08-07T15:05:00.000Z GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test https://www.biopharmawatch.com/news/FEMY/femasys-secures-30-million-private-placement BiopharmaWatch en 2026-08-07T13:25:00.000Z Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million https://www.biopharmawatch.com/news/RCEL/avita-medical-participation-canaccord-genuity-conference BiopharmaWatch en 2026-08-07T12:45:00.000Z AVITA Medical Announces Participation at Canaccord Genuity Growth Conference https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-07T12:45:00.000Z Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-q2-2026-results-dnase-platform BiopharmaWatch en 2026-08-07T12:35:00.000Z Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-corporate-update-q2-2026 BiopharmaWatch en 2026-08-07T12:30:00.000Z Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-1-study-nbip-1968-obesity BiopharmaWatch en 2026-08-07T12:30:00.000Z Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist https://www.biopharmawatch.com/news/LTRN/lantern-pharma-q2-2026-results-report BiopharmaWatch en 2026-08-07T12:00:00.000Z Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-q2-2026-results-cypath-lung BiopharmaWatch en 2026-08-07T12:00:00.000Z bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung https://www.biopharmawatch.com/news/HUMA/humacyte-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-07T12:00:00.000Z Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 https://www.biopharmawatch.com/news/LFWD/lifeward-report-q2-2026-results-august-14 BiopharmaWatch en 2026-08-07T12:00:00.000Z Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026 https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-presents-pk-pd-modeling-piktor-trial BiopharmaWatch en 2026-08-07T11:30:00.000Z Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference https://www.biopharmawatch.com/news/SNGX/soligenix-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-07T11:30:00.000Z Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-q2-2026-results BiopharmaWatch en 2026-08-07T11:05:00.000Z Treace Medical Concepts Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-08-07T11:00:00.000Z Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/NHC/nhc-reports-second-quarter-2026-earnings BiopharmaWatch en 2026-08-07T11:00:00.000Z NHC Reports Second Quarter 2026 Earnings https://www.biopharmawatch.com/news/NRXP/fda-first-cycle-review-preservative-free-ketamine BiopharmaWatch en 2026-08-07T11:00:00.000Z FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-07T11:00:00.000Z Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-07T11:00:00.000Z Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q2-2026-results BiopharmaWatch en 2026-08-07T11:00:00.000Z Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-record-q2-2026-results BiopharmaWatch en 2026-08-07T10:50:00.000Z ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results